The FDA said Wednesday that the biosimilar Semglee is interchangeable with the widely used fast-acting insulin Lantus. A biosimilar is a near copy of an injected biologic medicine that’s manufactured inside living cells, the Associated Press reported. A typical month’s supply of Semglee injector pens cost about $150 to $190 without insurance, compared to $340 to $520 for Lantus.
Semglee is from Viatris Inc., which is seeking FDA approval of another biosimilar of a long-lasting insulin. “These products are highly similar, but much more affordable,” McGowan told the AP.
Only 20 of 29 FDA-approved biosimilars — for cancer and immune disorders like rheumatoid arthritis — are currently available in the United States, Sean McGowan, head of biosimilars at AmerisourceBergen, a leading drug wholesaler, told the AP. More information
U.S. sales of biosimilars are lower than in Europe due to factors such as red tape, lengthy patents and opposition from brand-name drug makers, the AP said. From 2020 to 2024, savings from the use of biosimilars will exceed $100 billion in the United States, health data firm IQVIA suggests.
SOURCE: Associated Press Visit the National Institute of Diabetes and Digestive and Kidney Diseases for more on insulin.
News Highlights Health
- FDA Approves Automatic Use of Cheaper Generic Insulin – Consumer Health News
- Check all news and articles from the Health news information updates.